Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma has reported that their RNAi therapeutic candidate, imdusiran, combined with a short course of interferon, has achieved a functional cure in 50% of patients with chronic hepatitis B virus (cHBV) who had baseline HBsAg levels below 1000 IU/mL. Overall, 25% of patients in the trial reached a functional cure, marking a promising advancement in cHBV treatment. These results indicate potential for a finite curative treatment for cHBV patients worldwide.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
